{"id":"NCT00945958","sponsor":"Sun Pharma Advanced Research Company Limited","briefTitle":"Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2012-06","completion":"2012-06","firstPosted":"2009-07-24","resultsPosted":"2016-05-05","lastUpdate":"2021-03-09"},"enrollment":161,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"SPARC0913","otherNames":[]}],"arms":[{"label":"SPARC0913","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the long-term safety of SPARC0913. A multicenter, open label, non-randomized, uncontrolled, single group assignment, safety study of subjects with primary open angle glaucoma or ocular hypertension is planned. Subjects will receive study medication for a period of 24-weeks.","primaryOutcome":{"measure":"Number of Subjects With AEs","timeFrame":"24 weeks","effectByArm":[{"arm":"SPARC","deltaMin":140,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["35898518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":161},"commonTop":["Eye pain, ocular hyperemia, growh of eyelashes","Influenza, Sinusitis, Conjunctivitis viral, Tooth infection","Dizziness,Visual field defect","Osteoporosis","Edema peripheral"]}}